Constitutive activation of p62/Sequestosome-1-mediated proteaphagy regulates proteolysis and impairs cell death in bortezomib-resistant mantle cell lymphoma
Simple Summary To decipher the molecular mechanism underlying the resistance of a
significant fraction of mantle cell lymphoma (MCL) patients to the first-in-class proteasome …
significant fraction of mantle cell lymphoma (MCL) patients to the first-in-class proteasome …
Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma
Y Kuroda, D Koyama, J Kikuchi, S Mori, T Ichinohe… - Leukemia Research, 2021 - Elsevier
Mantle cell lymphoma (MCL) is usually resistant to the current standard-of-care regimens
and also to novel agents such as the proteasome inhibitor bortezomib. A better prognosis of …
and also to novel agents such as the proteasome inhibitor bortezomib. A better prognosis of …
Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma
M Gonzalez-Santamarta, G Quinet… - … and Disease: From …, 2020 - Springer
Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ)
significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell …
significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell …
A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells
E Milan, T Perini, M Resnati, U Orfanelli, L Oliva… - Autophagy, 2015 - Taylor & Francis
Multiple myeloma (MM) is the paradigmatic proteasome inhibitor (PI) responsive cancer, but
many patients fail to respond. An attractive target to enhance sensitivity is (macro) …
many patients fail to respond. An attractive target to enhance sensitivity is (macro) …
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP …
Despite the promising introduction of the proteasome inhibitor bortezomib in the treatment of
mantle cell lymphoma (MCL), not all patients respond, and resistance often appears after …
mantle cell lymphoma (MCL), not all patients respond, and resistance often appears after …
Mucin 20 modulates proteasome capacity through c‐Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma
X Wang, F Shirazi, W Yan, X Liu… - Journal of Cellular …, 2021 - Wiley Online Library
Mantle cell lymphoma (MCL) is a haematologic malignancy. The proteasome inhibitor (PI)
bortezomib has been approved to treat MCL, but resistance has emerged through …
bortezomib has been approved to treat MCL, but resistance has emerged through …
The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma
R Arkwright, TM Pham, JA Zonder… - Expert opinion on drug …, 2017 - Taylor & Francis
Introduction: Mantle cell lymphoma (MCL) is an incurable, often aggressive B-cell
malignancy. Bortezomib (BTZ), the 20S proteasome inhibitor was originally developed and …
malignancy. Bortezomib (BTZ), the 20S proteasome inhibitor was originally developed and …
The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle …
G Hutter, M Rieken, A Pastore, O Weigert… - Annals of …, 2012 - Springer
Single-agent bortezomib, a potent, selective, and reversible inhibitor of the 26S proteasome,
has demonstrated clinical efficacy in relapsed and refractory mantle cell lymphoma (MCL) …
has demonstrated clinical efficacy in relapsed and refractory mantle cell lymphoma (MCL) …
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4
Y Zang, SM Thomas, ET Chan, CJ Kirk, ML Freilino… - Autophagy, 2012 - Taylor & Francis
The proteasome inhibitor bortezomib has shown remarkable clinical success in the
treatment of multiple myeloma. However, the efficacy and mechanism of action of …
treatment of multiple myeloma. However, the efficacy and mechanism of action of …
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma
MA Weniger, EG Rizzatti, P Perez-Galan, D Liu… - Clinical Cancer …, 2011 - AACR
Purpose: Proteasome inhibition disrupts protein homeostasis and induces apoptosis. Up to
50% of patients with relapsed mantle cell lymphoma (MCL) respond to bortezomib. We used …
50% of patients with relapsed mantle cell lymphoma (MCL) respond to bortezomib. We used …